Intellia Therapeutics (NASDAQ:NTLA) Given New $84.00 Price Target at SVB Leerink

Intellia Therapeutics (NASDAQ:NTLA – Get Rating) had its price objective decreased by SVB Leerink from $86.00 to $84.00 in a research note issued to investors on Monday morning, Benzinga reports. SVB Leerink currently has an outperform rating on the stock.

A number of other brokerages have also commented on NTLA. Credit Suisse Group cut their price target on Intellia Therapeutics from $109.00 to $88.00 and set an outperform rating for the company in a report on Tuesday, December 6th. Raymond James dropped their price target on Intellia Therapeutics from $127.00 to $124.00 and set an outperform rating on the stock in a research report on Friday, November 4th. Wells Fargo & Company decreased their price objective on Intellia Therapeutics from $135.00 to $120.00 and set an overweight rating for the company in a report on Wednesday, January 4th. Chardan Capital lifted their target price on Intellia Therapeutics from $121.00 to $129.00 and gave the stock a buy rating in a research note on Monday, November 14th. Finally, JMP Securities cut Intellia Therapeutics from an outperform rating to a market perform rating in a report on Thursday, January 19th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus target price of $102.61.

Intellia Therapeutics Stock Up 6.0 %

NTLA opened at $35.88 on Monday. The firm has a market capitalization of $2.82 billion, a P/E ratio of -6.11 and a beta of 1.93. The firm’s 50 day moving average is $40.26 and its 200-day moving average is $52.48. Intellia Therapeutics has a 52-week low of $32.44 and a 52-week high of $104.87.

Intellia Therapeutics (NASDAQ:NTLA – Get Rating) last announced its quarterly earnings results on Thursday, November 3rd. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.31) by ($0.18). Intellia Therapeutics had a negative net margin of 859.92% and a negative return on equity of 47.79%. The firm had revenue of $13.27 million for the quarter, compared to analyst estimates of $13.60 million. Equities analysts expect that Intellia Therapeutics will post -6.02 earnings per share for the current fiscal year.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 6,673 shares of Intellia Therapeutics stock in a transaction on Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total value of $248,302.33. Following the transaction, the chief executive officer now directly owns 766,825 shares of the company’s stock, valued at $28,533,558.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Glenn Goddard sold 2,427 shares of the business’s stock in a transaction dated Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total transaction of $90,308.67. Following the completion of the sale, the chief financial officer now owns 15,404 shares of the company’s stock, valued at $573,182.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO John M. Leonard sold 6,673 shares of the company’s stock in a transaction dated Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total transaction of $248,302.33. Following the sale, the chief executive officer now directly owns 766,825 shares of the company’s stock, valued at approximately $28,533,558.25. The disclosure for this sale can be found here. Insiders have sold a total of 11,608 shares of company stock valued at $431,934 over the last ninety days. 2.60% of the stock is owned by company insiders.

Institutional Trading of Intellia Therapeutics

Several hedge funds have recently made changes to their positions in NTLA. MetLife Investment Management LLC lifted its holdings in Intellia Therapeutics by 54.7% during the 1st quarter. MetLife Investment Management LLC now owns 37,362 shares of the company’s stock worth $2,715,000 after buying an additional 13,209 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Intellia Therapeutics by 2.7% in the first quarter. Rhumbline Advisers now owns 98,247 shares of the company’s stock valued at $7,140,000 after purchasing an additional 2,620 shares during the period. Cibc World Market Inc. raised its position in Intellia Therapeutics by 47.3% during the first quarter. Cibc World Market Inc. now owns 4,740 shares of the company’s stock worth $344,000 after acquiring an additional 1,522 shares during the last quarter. Blair William & Co. IL grew its holdings in shares of Intellia Therapeutics by 11.9% during the first quarter. Blair William & Co. IL now owns 10,362 shares of the company’s stock worth $753,000 after buying an additional 1,100 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in Intellia Therapeutics in the first quarter valued at approximately $307,000. Hedge funds and other institutional investors own 85.61% of the company’s stock.

Intellia Therapeutics Company Profile

(Get Rating)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.